menu
    • menu
    [{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vesper Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vesper Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vesper Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saniona \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NMD1343","moa":"CIC-1","graph1":"Neurology","graph2":"Phase I","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRX4204","moa":"RXR nuclear receptor","graph1":"Neurology","graph2":"Phase I","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IO Biotech \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Saniona

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Saniona

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAN711

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Acadia Pharmaceuticals

                            Deal Size : $610.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

                            Details : Under the license agreement, Acadia will acquire exclusive rights to further the clinical development of SAN711, which is being studied as a treatment for Essential Tremors.

                            Product Name : SAN711

                            Product Type : Other Small Molecule

                            Upfront Cash : $28.0 million

                            November 26, 2024

                            Lead Product(s) : SAN711

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Acadia Pharmaceuticals

                            Deal Size : $610.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IO Biotech

                            Denmark arrow
                            EPS
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Io Therapeutics Presents IRX4204 Data for Aging, Parkinson’s, and Alzheimer’s

                            Details : IRX4204 is a highly potent and highly selective, orally available, third generation RXR agonist compound which IS being tested in early phase clinical trials in patients with Parkinson’s disease

                            Product Name : IRX4204

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 07, 2024

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novo Nordisk

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novo's Older Obesity Drug Shows Biological Effect on Alzheimer's Patients in Small Trial

                            Details : Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is investigated for the treatment of patients with mild alzheimer's disease.

                            Product Name : Victoza

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            July 29, 2024

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vesper Bio

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Vesper Bio

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VES001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vesper Bio Completes Single Ascending Dose Stage for VES001 in Dementia Trial

                            Details : VES001, a oral small molecule sortilin receptor inhibitor, is presently completed Phase I evaluation for the treatment of Frontotemporal Dementia.

                            Product Name : VES001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 30, 2024

                            Lead Product(s) : VES001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vesper Bio

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Vesper Bio

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VES001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vesper Bio Reports Successful Phase I Study for Frontotemporal Dementia Treatment

                            Details : VES001 is a first-in-class oral, brain-penetrant, small molecule sortilin receptor inhibitor, is presently undergoing evaluation for the treatment of Frontotemporal Dementia.

                            Product Name : VES001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 09, 2024

                            Lead Product(s) : VES001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vesper Bio

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Vesper Bio

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VES001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vesper Bio doses First Volunteer in Phase I Study of First-In-Class Oral Treatment for Frontotemporal Dementia...

                            Details : VES001, a small molecule sortilin receptor inhibitor, is presently undergoing evaluation in ongoing Phase I clinical trials for the treatment of Frontotemporal Dementia.

                            Product Name : VES001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 12, 2023

                            Lead Product(s) : VES001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            NMD PHARMA

                            Denmark arrow
                            EPS
                            Not Confirmed

                            NMD PHARMA

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NMD1343

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NMD Pharma Initiates Phase I Safety, Tolerability and Pharmacokinetics Study of NMD1343

                            Details : NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion channel, and NMD Pharma’s second clinical development candidate

                            Product Name : NMD1343

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 23, 2023

                            Lead Product(s) : NMD1343

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Saniona

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Saniona

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAN711

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

                            Details : Data from the trial demonstrated that SAN711 was safe and well tolerated across all dosing cohorts with a favorable absorption and distribution profile. There were no serious adverse events, and all subjects completed the study.

                            Product Name : SAN711

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 30, 2022

                            Lead Product(s) : SAN711

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Saniona

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Saniona

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAN711

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Saniona Initiates Positron Emission Tomography (PET) Stage of SAN711 Phase 1 Clinical Trial

                            Details : SAN711 is an investigational, potential first-in-class positive allosteric modulator of GABA-A α3 receptors, may have the potential to restore spinal inhibitory tone and prevent abnormal pain signaling to the brain.

                            Product Name : SAN711

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 24, 2022

                            Lead Product(s) : SAN711

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Saniona

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Saniona

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAN711

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5 Negative Allosteric Modulator Program from ...

                            Details : The termination of the GABAa5 program provides Saniona with rights to a portfolio of more than 800 molecules; the company intends to evaluate their applicability in rare diseases.

                            Product Name : SAN711

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 11, 2020

                            Lead Product(s) : SAN711

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth